{"id":"https://openalex.org/W2362827599","doi":"https://doi.org/10.1007/s00280-016-3056-0","title":"Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma","display_name":"Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma","publication_year":2016,"publication_date":"2016-05-11","ids":{"openalex":"https://openalex.org/W2362827599","doi":"https://doi.org/10.1007/s00280-016-3056-0","mag":"2362827599","pmid":"https://pubmed.ncbi.nlm.nih.gov/27169794"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-016-3056-0","doi":"https://doi.org/10.1007/s00280-016-3056-0","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-016-3056-0","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005521408","display_name":"Oliver Edgar Bechter","orcid":"https://orcid.org/0000-0003-0667-3284","observed_orcids":["https://orcid.org/0000-0003-0667-3284"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Oliver E. Bechter","raw_affiliation_strings":["Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium. oliver.bechter@uzleuven.be","Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven \u2013 University of Leuven, 3000, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium. oliver.bechter@uzleuven.be","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]},{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven \u2013 University of Leuven, 3000, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026692589","display_name":"Herlinde Dumez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Herlinde Dumez","raw_affiliation_strings":["Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071930365","display_name":"Jo Costermans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Jo Costermans","raw_affiliation_strings":["Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024524838","display_name":"Kevin Punie","orcid":"https://orcid.org/0000-0002-1162-7963","observed_orcids":["https://orcid.org/0000-0002-1162-7963"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Kevin Punie","raw_affiliation_strings":["Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072906560","display_name":"Karl Hsu","orcid":"https://orcid.org/0000-0003-3137-1202","observed_orcids":["https://orcid.org/0000-0003-3137-1202"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karl Hsu","raw_affiliation_strings":["Sanofi, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111815334","display_name":"Jean-Fran\u00e7ois Dedieu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Fran\u00e7ois Dedieu","raw_affiliation_strings":["Sanofi, Chilly-Mazarin, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Chilly-Mazarin, France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017761236","display_name":"Anne-Fr\u00e9d\u00e9rique Ghuysen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Anne-Fr\u00e9d\u00e9rique Ghuysen","raw_affiliation_strings":["Sanofi, Chilly-Mazarin, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Chilly-Mazarin, France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007470532","display_name":"Elisa Francesconi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Elisa Francesconi","raw_affiliation_strings":["Sanofi, Vitry-sur-Seine, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Vitry-sur-Seine, France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102727672","display_name":"Jyoti Sharma","orcid":"https://orcid.org/0000-0001-6344-3085","observed_orcids":["https://orcid.org/0000-0001-6344-3085"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jyoti Sharma","raw_affiliation_strings":["Sanofi, Bridgewater, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Bridgewater, NJ, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100418873","display_name":"Li Liu","orcid":"https://orcid.org/0000-0002-9801-128X","observed_orcids":["https://orcid.org/0000-0002-9801-128X"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Liu","raw_affiliation_strings":["Sanofi, Bridgewater, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Bridgewater, NJ, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021550191","display_name":"Patrick Sch\u00f6ffski","orcid":"https://orcid.org/0000-0001-5980-030X","observed_orcids":["https://orcid.org/0000-0001-5980-030X"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Patrick Sch\u00f6ffski","raw_affiliation_strings":["Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5005521408"],"corresponding_institution_ids":["https://openalex.org/I2800231306","https://openalex.org/I99464096"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.1732,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.6099178,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"78","issue":"1","first_page":"83","last_page":"90"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/tablet-formulation","display_name":"tablet formulation","score":0.9729999899864197},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7860000133514404},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8420000076293945},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9700000286102295},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7519999742507935},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7390000224113464},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.972000002861023},{"id":"https://openalex.org/keywords/maculopapular-rash","display_name":"maculopapular rash","score":0.8360000252723694},{"id":"https://openalex.org/keywords/lipase-elevation","display_name":"lipase elevation","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7175930142402649},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.5476497411727905},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5063110589981079},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.492367148399353},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.458450049161911},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.4271778166294098},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.41394510865211487},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3748890161514282},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2815045714378357},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.26149386167526245},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24726960062980652},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.12208271026611328},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002214","descriptor_name":"Capsules","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008223","descriptor_name":"Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s00280-016-3056-0","doi":"https://doi.org/10.1007/s00280-016-3056-0","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-016-3056-0","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:27169794","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27169794","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:lirias2repo.kuleuven.be:123456789/543144","doi":null,"is_oa":false,"landing_page_url":"https://lirias.kuleuven.be/handle/123456789/543144","pdf_url":null,"source":{"id":"https://openalex.org/S4306401954","display_name":"Lirias (KU Leuven)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I99464096","host_organization_name":"KU Leuven","host_organization_lineage":["https://openalex.org/I99464096"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer Chemotherapy and Pharmacology, vol. 78 (1), (83-90)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1529496601","https://openalex.org/W1667020473","https://openalex.org/W1975685376","https://openalex.org/W1979937839","https://openalex.org/W1980705784","https://openalex.org/W1981711832","https://openalex.org/W1996222881","https://openalex.org/W1997870023","https://openalex.org/W2009886463","https://openalex.org/W2014096417","https://openalex.org/W2022948980","https://openalex.org/W2030899725","https://openalex.org/W2031885687","https://openalex.org/W2066564017","https://openalex.org/W2070073293","https://openalex.org/W2070732456","https://openalex.org/W2071341510","https://openalex.org/W2071591166","https://openalex.org/W2080551472","https://openalex.org/W2083293423","https://openalex.org/W2088460013","https://openalex.org/W2114553148","https://openalex.org/W2120725164","https://openalex.org/W2125357652","https://openalex.org/W2126390772","https://openalex.org/W2129172946","https://openalex.org/W2134861285","https://openalex.org/W2136269815","https://openalex.org/W2148181778","https://openalex.org/W2151172909","https://openalex.org/W2165404212","https://openalex.org/W2168023789","https://openalex.org/W2170908060","https://openalex.org/W2603765845","https://openalex.org/W4242290472"],"related_works":["https://openalex.org/W2794860260","https://openalex.org/W2151172909","https://openalex.org/W2593681767","https://openalex.org/W2599291739","https://openalex.org/W2022948980","https://openalex.org/W2607479181","https://openalex.org/W1979937839","https://openalex.org/W2514569171","https://openalex.org/W2557486167","https://openalex.org/W2921476638"],"abstract_inverted_index":null,"counts_by_year":[{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}